- Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616–20.
- Miner P, Katz P, Chen Y, Sostek M. Reanalysis of intragastric pH results based on updated correction factors for slimline and zinetics 24 single-use pH catheters. Am J Gastroenterol 2006;101:404–5, 406.
- Röhss K, Wilder-Smith C, Nauclér E, Jansson L. Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Invest 2004;24:1–7.
- Kahrilas P, Falk G, Johnson D, Schmitt C, Collins D, Whipple J et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000;14:1249–58.
- Richter J, Kahrilas J, Johanson J, Maton P, Breiter J, Hwang C et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656–65.
- Castell D, Kahrilas P, Richter J, Vakil N, Johnson D, Zuckerman S et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575–83.
- Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K et al. A randomised comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive esophagitis: the EXPO study. Aliment Pharmacol Ther 2005;21:739–46.
- Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005;22:803–11.
- Lauritsen K, Devière J, Bigard M-A, Bayerdörffer E, Mózsik G, Murray F et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux esophagitis: Metropole study results. Aliment Pharmacol Ther 2003;17:333–41.
- Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:926–35.
- Tulassay Z, Kryszewski A, Dite P, Kleckowski D, Rudzinski J, Bartuzi Z et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001:13:1457-65.
- Veldhuyzen van Zanten S, Lauritsen K, Delchier J-C, Labenz J, de Argila CM, Lind T et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000;14:1605–1611.
Not signed in
Page tools
Share price
- London
-
33.32 GBP - New York
-
51.51 USD - Stockholm
-
374.10 SEK
At 09-Sep-2010 15:53 GMT
Detailed share price